Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone

Clinical Cancer Research

Volumn 18, Issue 16, 2012, Pages 4415-4424

  Branstetter, Daniel G ^a   Nelson, Scott D ^b   Manivel, J Carlos ^c   Blay, Jean Yves ^d   Chawla, Sant ^e   Thomas, David M ^f   Jun, Susie ^g   Jacobs, Ira ^g  

^a AMGEN INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITÉ LYON 1   (France)

^e Sarcoma Oncology Center   (United States)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ADULT; ARTICLE; CANCER RECURRENCE; CELL PROLIFERATION; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MONONUCLEAR CELL; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OSSIFICATION; OSTEOBLASTOMA; OSTEOCLASTOMA; OSTEOID; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL; TISSUE DIFFERENTIATION; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR VOLUME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; FEMALE; GIANT CELL TUMOR OF BONE; HUMANS; MALE; OSTEOGENESIS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865073466     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0578     Document Type: Article

References (50)

1. Mendenhall WM, Zlotecki RA, Scarborough MT, Gibbs CP, Mendenhall NP. Giant cell tumor of bone. Am J Clin Oncol 2006;29:96-9.
2. Atkins GJ, Haynes DR, Graves SE, Evdokiou A, Hay S, Bouralexis S, et al. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res 2000;15:640-9.
3. Atkins GJ, Kostakis P, Vincent C, Farrugia AN, Houchins JP, Findlay DM, et al. RANK expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J Bone Miner Res 2006;21:1339-49.
4. Forsyth RG, De Boeck G, Baelde JJ, Taminiau AH, Uyttendaele D, Roels H, et al. CD33+ CD14- phenotype is characteristic of multinuclear osteoclast-like cells in giant cell tumor of bone. J Bone Miner Res 2009;24:70-7.
5. Garcia R, Inwards C, Unni K. Benign bone tumors - recent developments. Semin Diagn Pathol 2011;28:73-85.
6. Goldring SR, Roelke MS, Petrison KK, Bhan AK. Human giant cell tumors of bone identification and characterization of cell types. J Clin Invest 1987;79:483-91.
7. Huang L, Xu J, Wood DJ, Zheng MH. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol 2000;156:761-7.
8. Roux S, Amazit L, Meduri G, Guiochon-Mantel A, Milgrom E, Mariette X. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am J Clin Pathol 2002;117:210-6.
9. Schwartz H. Giant cell tumor of bone. Compr Ther 1993;19:63-8.
10. Thomas DM, Skubitz KM. Giant cell tumor of bone. Curr Opin Oncol 2009;21:338-44.
11. Werner M. Giant cell tumour of bone: morphological, biological, and histogenetical aspects. Int Orthop 2006;30:484-9.
12. Zheng MH, Robbins P, Xu J, Huang L, Wood DJ, Papadimitriou JM. The histogenesis of giant cell tumour of bone: a model of interaction between neoplastic cells and osteoclasts. Histol Histopathol 2001;16:297-307.
13. Skubitz KM, Cheng EY, Clohisy DR, Thompson RC, Skubitz AP. Gene expression in giant-cell tumors. J Lab Clin Med 2004;144:193-200.
14. Huang L, Teng XY, Cheng YY, Lee KM, Kumta SM. Expression of preosteoblast markers and Cbfa-1 and Osterix gene transcripts in stromal tumour cells of giant cell tumour of bone. Bone 2004;34:393-401.
15. Nishimura M, Yuasa K, Mori K, Miyamoto N, Ito M, Tsurudome M, et al. Cytological properties of stromal cells derived from giant cell tumor of bone (GCTSC) which can induce osteoclast formation of human blood monocytes without cell to cell contact. J Orthop Res 2005;23:979-87.
16. Robinson D, Segal M, Nevo Z. Giant cell tumor of bone. The role of fibroblast growth factor 3 positive mesenchymal stem cells in its pathogenesis. Pathobiology 2002;70:333-42.
17. Wulling M, Delling G, Kaiser E. The origin of the neoplastic stromal cell in giant cell tumor of bone. Hum Pathol 2003;34:983-93.
18. Emura I, Inoue Y, Ohnishi Y, Morita T, Saito H, Tajima T. Histochemical, immunohistochemical and ultrastructural investigations of giant cell tumors of bone. Acta Pathol Jpn 1986;36:691-702.
19. Fornasier VL, Protzner K, Zhang I, Mason L. The prognostic significance of histomorphometry and immunohistochemistry in giant cell tumors of bone. Hum Pathol 1996;27:754-60.
20. Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010;11:275-80.
21. Lewiecki EM. Clinical use of denosumab for the treatment for postmenopausal osteoporosis. Curr Med Res Opin 2010;26:2807-12.
22. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. A randomised, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in men with castration-resistant prostate cancer. Lancet 2011;377:813-22.
23. Henry D, Costa L, Goldwasser F, Hirsch V, Hungria V, Prausova J, et al. A randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-32.
24. Stopeck A, Lipton A, Body JJ, Steger GG, Tonkin KS, de Boer R, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132-9.
25. Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010;468:103-7.
26. Murata A, Fujita T, Kawahara N, Tsuchiya H, Tomita K. Osteoblast lineage properties in giant cell tumors of bone. J Orthop Sci 2005;10:581-8.
27. Robinson D, Einhorn TA. Giant cell tumor of bone: a unique paradigm of stromal-hematopoietic cellular interactions. J Cell Biochem 1994;55:300-3.
28. Butler MG, Dahir GA, Schwartz HS. Molecular analysis of transforming growth factor beta in giant cell tumor of bone. Cancer Genet Cytogenet 1993;66:108-12.
29. Horvai AE, Kramer MJ, Garcia JJ, O'Donnell RJ. Distribution and prognostic significance of human telomerase reverse transcriptase (hTERT) expression in giant-cell tumor of bone. Mod Pathol 2008;21:423-30.
30. Schwartz HS, Butler MG, Jenkins RB, Miller DA, Moses HL. Telomeric associations and consistent growth factor overexpression detected in giant cell tumor of bone. Cancer Genet Cytogenet 1991;56:263-76.
31. Schwartz HS, Eskew JD, Butler MG. Clonality studies in giant cell tumor of bone. J Orthop Res 2002;20:387-90.
32. Lau YS, Sabokbar A, Gibbons CL, Giele H, Athanasou N. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. Hum Pathol 2005;36:945-54.
33. Baud'huin M, Renault R, Charrier C, Riet A, Moreau A, Brion R, et al. Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis. J Pathol 2010;221:77-86.
34. Liao TS, Yurgelun MB, Chang SS, Zhang HZ, Murakami K, Blaine TA, et al.Recruitment of osteoclast precursors by stromal cell derived factor-1 (SDF-1) in giant cell tumor of bone. J Orthop Res 2005;23:203-9.
35. + macrophage-like cell migration. J Cell Biochem 1998;70:121-9.
36. Joyner CJ, Quinn JM, Triffitt JT, Owen ME, Athanasou NA. Phenotypic characterisation of mononuclear and multinucleated cells of giant cell tumour of bone. Bone Miner 1992;16:37-48.
37. Miyamoto N, Higuchi Y, Tajima M, Ito M, Tsurudome M, Nishio M, et al. Spindle-shaped cells derived from giant-cell tumor of bone support differentiation of blood monocytes to osteoclast-like cells. J Orthop Res 2000;18:647-54.
38. Roux S, Quinn J, Pichaud F, Orcel P, Chastre E, Jullienne A, et al. Human cord blood monocytes undergo terminal osteoclast differentiation in vitro in the presence of culture medium conditioned by giant cell tumor of bone. J Cell Physiol 1996;168:489-98.
39. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15:2-12.
40. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13:2412-24.
41. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-23.
42. Atkins GJ, Bouralexis S, Haynes DR, Graves SE, Geary SM, Evdokiou A, et al. Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone 2001;28:370-7.
43. James IE, Dodds RA, Olivera DL, Nuttall ME, Gowen M. Human osteoclastoma-derived stromal cells: correlation of the ability to form mineralized nodules in vitro with formation of bone in vivo. J Bone Miner Res 1996;11:1453-60.
44. Kudo N, Ogose A, Ariizumi T, Kawashima H, Hotta T, Hatano H, et al. Expression of bone morphogenetic proteins in giant cell tumor of bone. Anticancer Res 2009;29:2219-25.
45. Mundy GR, Elefteriou F. Boning up on ephrin signaling. Cell 2006;126:441-3.
46. Pierroz DD, Rufo A, Bianchi EN, Glatt V, Capulli M, Rucci N, et al. Beta-Arrestin2 regulates RANKL and ephrins gene expression in response to bone remodeling in mice. J Bone Miner Res 2009;24:775-84.
47. Sims NA, Gooi JH. Bone remodeling: multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol 2008;19:444-51.
48. Xing W, Kim J, Wergedal J, Chen ST, Mohan S. Ephrin B1 regulates bone marrow stromal cell differentiation and bone formation by influencing TAZ transactivation via complex formation with NHERF1. Mol Cell Biol 2010;30:711-21.
49. Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 2006;4:111-21.
50. Tse LF, Wong KC, Kumta SM, Huang L, Chow TC, Griffith JF. Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study. Bone 2008;42:68-73.